• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The ACURASYS trial: Neuromuscular blockade in early ARDS [Classics Series]

byAndrew Cheung, MD MBA
April 3, 2015
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with severe acute respiratory distress syndrome (ARDS), treatment with neuromuscular blockade in the first 48 hours significantly reduced 90-day and 28-day mortality when compared to placebo.

2. The group treated with the neuromuscular blocker also experienced significantly lower rates of barotrauma and there were no differences between the groups in terms of ICU-acquired paresis.

Original Date of Publication: September 2010

Study Rundown: Acute respiratory distress syndrome (ARDS) is commonly encountered in patients requiring intensive care, and is characterized by hypoxemic respiratory failure, bilateral chest infiltrates, and high mortality. While the ARMA trial had demonstrated that lung-protective mechanical ventilation was effective, no other measures had convincingly reduced mortality from ARDS at the time this study was conducted. The ARDS et Curarisation Systematique (ACURASYS) trial was conducted to evaluate if early treatment of ARDS with cisatracurium besylate, a neuromuscular blocker, would significantly improve outcomes.

In summary, treating patients with severe ARDS with neuromuscular blockade in the first 48 hours of onset significantly reduced 90-day mortality and 28-day mortality. Patients receiving neuromuscular blockade also experienced significantly lower rates of barotrauma, while there were no differences between the two groups in the rate of ICU-acquired paresis. One criticism of the study is that the authors did not use train-of-four stimulation to assess the extent of neuromuscular blockade, and based their dosing solely on a previous smaller study.

Click to read the study in NEJM

RELATED REPORTS

#VisualAbstract: Convalescent Plasma Reduces Mortality Rate in COVID-19-Induced Acute Respiratory Distress Syndrome

Tocilizumab not superior to standard care in randomized controlled trial for severe COVID-19 patients

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

In-Depth [randomized controlled trial]: A total of 340 patients from 40 intensive care unit (ICUs) from across France were enrolled and randomized as part of this trial. Patients were eligible for the trial if they were receiving invasive mechanical ventilation, had acute hypoxemic respiratory failure, and met severe ARDS criteria (i.e., PaO2:FiO2 ratio <150 with positive end-expiratory pressure ≥5 cm H2O, tidal volumes between 6-8 mL/kg, bilateral pulmonary infiltrates, non-cardiogenic edema) for ≤48 hours. Exclusion criteria included age <18 years, treatment with neuromuscular blockade at enrolment, known pregnancy, increased intracranial pressure, severe chronic liver disease, bone-marrow transplantation or chemotherapy-induced neutropenia, and pneumothorax, amongst others. Enrolled patients were randomized to receive cisatracurium besylate (i.e., 15 mg rapid infusion, followed by continuous infusion of 37.5 mg/hour) or placebo infusion. The primary outcomes were in-hospital and 90-day mortality. The secondary outcomes included 28-day mortality, the rate of barotrauma, and the rate of ICU-acquired paresis.

The only baseline difference between the two groups was a significantly lower PaO2:FiO2 ratio in the cisatracurium group, as compared to the placebo group (p=0.03). After adjusting for baseline PaO2:FiO2, treatment with cisatracurium significantly reduced 90-day mortality as compared with placebo (HR 0.68; 95%CI 0.48-0.98). Moreover, 28-day mortality was also significantly lower in the cisatracurium group (ARR -9.6%; 95%CI -19.2 to -0.2%). Patients in the cisatracurium group also experienced significantly lower rates of barotrauma (RR 0.43; 95%CI 0.20-0.93) and ICU-acquired paresis (p=0.51) when compared to patients receiving placebo.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: acurasysARDScisatracurium
Previous Post

Xpert MTB/RIF assay more sensitive than smear microscopy for diagnosing tuberculosis

Next Post

Alternative outpatient antibiotics as effective as standard antibiotic injections for severe infantile infections

RelatedReports

#VisualAbstract: Convalescent Plasma Reduces Mortality Rate in COVID-19-Induced Acute Respiratory Distress Syndrome
StudyGraphics

#VisualAbstract: Convalescent Plasma Reduces Mortality Rate in COVID-19-Induced Acute Respiratory Distress Syndrome

December 8, 2023
Prescription of antibiotics for acute respiratory infections increasing
Emergency

Tocilizumab not superior to standard care in randomized controlled trial for severe COVID-19 patients

February 1, 2021
Critically ill COVID-19 patients may benefit from convalescent plasma therapy
Infectious Disease

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

April 9, 2020
#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China
StudyGraphics

#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

April 8, 2020
Next Post
Alternative outpatient antibiotics as effective as standard antibiotic injections for severe infantile infections

Alternative outpatient antibiotics as effective as standard antibiotic injections for severe infantile infections

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

Novel drug inhibits MLL leukemia progression in mice [PreClinical]

Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]

Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.